BRAF kinase inhibitors (BRAFi) like vemurafenib (Vem; marketed as Zelboraf) and dabrafenib (Dabra) have become the standard targeted therapy for melanoma patients with BRAF mutations [11,12]. This evidence concerns the gene BRAF and melanoma.